- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01349348
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
A Randomized, Double-blinded, Multicenter, Placebo Controlled, Parallel Designed Study, to Evaluate the Efficacy and Safety of Tolvaptan Tablet in Treatment of Patients With Cirrhosis Ascites, Using Diuretics as Initial Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
For symptoms of fluid retention due to liver diseases (ascites and/or lower extremity edema, i.e. hepatic edema), treatment generally starts with bed rest and a low-salt diet. Aldosterone antagonists and loop diuretics are commonly used diuretics in the treatment of fluid retention due to liver diseases. In aldosterone antagonists' therapy, nevertheless, hyperkalemia is frequently reported, slow onset of action and dose escalation needed also impair its effect. If aldosterone antagonists' therapy is ineffective, loop diuretics as strong diuretics are usually added up. However, Dose escalation of loop diuretics also boost the occurrence of hyponatremia and hypokalemia, and combination of the two drugs provided fastest onset of effectiveness with less adverse events. While, because both diuretics can cause sodium lose which is difficult to prevent and treat, hyponatremia is easy to occur. The combination of aldosterone antagonists and K-sparing diuretics reduces the occurrence of hypokalemia but have little effect on the prevention and treatment of hyponatremia. In addition, there are still some patients who are resistent to loop diuretics or intolerant of an effective diuretic dosage due to adverse events.
Tolvaptan increases the excretion of electrolyte-free water (aquaretic) without changing electrolytes excretion by inhibiting the water reabsorption of collecting duct in kidney. It is demonstrated that Tolvaptan increased urine volume without impairing renal function.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200001
- Renji Hospital, Shanghai Jiaotong University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Patients diagnosed with liver cirrhosis clinically or pathologically;
- Patients with ascites confirmed by Type-B ultrasound scan after receiving combination therapies of oral loop diuretics and aldosterone antagonists for at least 4 days with the fixed usage and dosage
- Inpatients or patients who can be hospitalized for this study from Day -3 (Screening) to Day 8 (the day for efficacy evaluation);
- Patients with body weight change within ±1.0 kg in the 2 days prior to initiation of treatment (Day -2 and Day -1)
- Age: 18 to 75 years, inclusive(at the time informed consent is obtained);
- Genders: men or women;
- Patients who have signed informed consent form.
Exclusion criteria:
Patients with any of the following diseases, complications or symptoms:
- Hepatic encephalopathy (hepatic coma of grade II or higher1));
- Malignant ascites (patients have tumor cells detected in ascites if malignant ascites be highly suspected);
- Uncontrolled spontaneous bacterial peritonitis;
- Patients who are likely to experience alimentary tract hemorrhage during the study;
- Heart failure (NYHA2) grade III or IV);
- Anuresis (daily urine volume is less than 100mL);
- Dysuria due to urinary tract stricture, urinary calculus, tumor in the urinary tract or other cause.
Patients with history of :
- Alimentary tract hemorrhage within 10 days prior to screening;
- Cerebral accident suffered within 30 days prior to screening;
- Past history of hypersensitivity or idiosyncratic reaction to benzazepine derivatives (Benazepril).
- Patients with systolic pressure below 90mmHg at screening;
Patients with any of the following abnormal laboratory parameters at screening:
- Serum creatinine >1.5x upper limit of normal range;
- Serum Na+>145mmol/L (or higher than upper limit of normal range);
- Serum K+>5.5mmol/L;
- Patients with Child-pugh score3)>12;
- Patients who are unable to take medicine orally;
- Female patients who are pregnant, lactating, or who are at child-bearing age without using acceptable contraceptive means;
- Patients who received blood products including albumin within 4 days prior to the initiation of treatment
- Patients who participated in any clinical trial other than tolvaptan within one month prior to screening;
- Patients who participated in Tolvaptan trials and took Tolvaptan previously;
- Patients otherwise judged by the investigator, to be inappropriate for inclusion in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tolvaptan 15mg
Tablet;15mg/tab
|
tablet, 15 mg, Qd, for 7 days
Other Names:
tablet, 7.5 mg, Qd, for 7 days
Other Names:
|
Experimental: Tolvaptan 7.5mg
Tablet;7.5mg/tab
|
tablet, 15 mg, Qd, for 7 days
Other Names:
tablet, 7.5 mg, Qd, for 7 days
Other Names:
|
Placebo Comparator: Placebo
Tolvaptan 0mg/tab
|
tablet, 7.5/15mg , Qd, 7days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in body weight after 7 days randomized treatment (Day 8).
Time Frame: 7 days
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in body weight after 4 days randomized treatment (Day 5);
Time Frame: 4days
|
4days
|
The rate of change from baseline in body weight after 4, 7 days randomized treatment (Day 5, Day 8);
Time Frame: 4 and 7 days
|
4 and 7 days
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Tang J, Wang Y, Han T, Mao Q, Cheng J, Ding H, Shang J, Zhang Q, Niu J, Ji F, Chen C, Jia J, Jiang X, Lv N, Gao Y, Wang Z, Wei Z, Chen Y, Zeng M, Mao Y. Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial. BMC Gastroenterol. 2020 Nov 19;20(1):391. doi: 10.1186/s12876-020-01536-0.
- Wang S, Zhang X, Han T, Xie W, Li Y, Ma H, Liebe R, Weng H, Ding HG. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia. BMC Gastroenterol. 2018 Sep 4;18(1):137. doi: 10.1186/s12876-018-0857-0.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 156-08-805-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ascites
-
Second Affiliated Hospital of Soochow UniversityNot yet recruiting
-
Sichuan Clover Biopharmaceuticals, Inc.Completed
-
Healthgen Biotechnology Corp.Completed
-
Sequana Medical N.V.CompletedMalignant AscitesGermany, Switzerland, United Kingdom
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Terminated
-
MovetisCompleted
-
Postgraduate Institute of Medical Education and...UnknownRefractory Ascites
-
University of AlbertaBecton, Dickinson and CompanyCompleted
-
Eastern Regional Medical CenterTerminatedMalignant AscitesUnited States
-
Mansoura UniversityCompleted
Clinical Trials on Tolvaptan
-
Otsuka Pharmaceutical Development & Commercialization...RecruitingAutosomal Recessive Polycystic Kidney (ARPKD)United States, United Kingdom, Belgium, Poland, France, Germany, Italy
-
Regional Hospital HolstebroAarhus University HospitalCompleted
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAutosomal Dominant Polycystic Kidney DiseaseUnited States
-
NYU Langone HealthWithdrawnSIADH | Cerebral Hyponatremia | Cerebral Salt-wasting Syndrome | Reset Hypothalamic OsmostatUnited States
-
Eli Lilly and CompanyActive, not recruitingPlaque Psoriasis | Psoriatic ArthritisIndia
-
Otsuka Pharmaceutical Co., Ltd.CompletedPolycystic Kidney, Autosomal DominantJapan
-
Otsuka Pharmaceutical Co., Ltd.CompletedAutosomal Dominant Polycystic Kidney Disease (ADPKD)Japan
-
University of North Carolina, Chapel HillOtsuka America PharmaceuticalCompletedHeart Diseases | Cardiovascular Diseases | Heart FailureUnited States
-
Otsuka Pharmaceutical Development & Commercialization...Otsuka Pharmaceutical Co., Ltd.CompletedInappropriate ADH Syndrome | Water Intoxication | Hyponatremias | Water-Electrolyte ImbalancesUnited States